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ABSTRACT
Background: Diabetic peripheral neuropathy (DPN) not only produces severe pain, tingling,
and numbness sensation in the involved limbs, but also limits physical function due to loss
of sensation. There are no recommended methods for clinical situations to measure these
signs and symptoms. Studies with high methodological quality use the modified Brief Pain
Inventory for Diabetic Peripheral Neuropathic pain (mBPI-DPN) scale and the short form
Screening of Activity Limitations and Safety Awareness (sSALSA) scale for measuring these
symptoms in DPN population. In order to capture a real change in the variables of interest,
the psychometric properties of that measure should be within acceptable limits. As these
two measures were not assessed for all of the psychometric properties, there was a need for
further evaluation.
Methods: Data were collected (n¼ 38 patients) in a longitudinal cohort study. Test–retest
reliability (0–4 weeks) and Responsiveness- Minimal Clinically Important Difference (MCID)
(0–12 weeks) were calculated between two sessions. Convergent validity was assessed
(between mBPI-DPN pain interference and sSALSA scale).
Results: Both measures demonstrated acceptable test–retest reliability (mBPI-DPN scale: ICC
¼ 0.61, SEM ¼ 12.92; the sSALSA scale: ICC ¼ 0.81, SEM ¼ 4.88) and convergent validity
(Spearman’s correlation coefficient r¼ 0.62). The computational methods used in different
methodologies to calculate MCID for the mBPI-DPN and the sSALSA scale were varied, hence
the magnitude of derived MCID scores also varied.
Conclusions: Our study have provided evidence to add to the scientific basis surrounding
the use of mBPI-DPN and sSALSA scales in DPN population, but standardization of these
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1. Introduction
Neuropathic Pain (NeP) is defined as ‘pain initiated
or caused by a primary lesion or dysfunction in
the nervous system’ by the Assessment Committee
of the Neuropathic Pain Special Interest Group
(NeuPSIG) of the International Association for the
Study of Pain (IASP) [1]. The main causes of NeP
vary globally [2]. In developing countries, infectious
diseases such as Human Immunodeficiency Virus
[3] and leprosy [4], trauma (due to war wounds and
amputations) [5] and radiculopathies related to spi-
nal column disease [2] are among the most com-
mon causes of NeP. In developed countries, diabetes
is considered to be one of the most common causes
of NeP [6].
According to the Centres for Disease Control
(2011), approximately 26 million American adults
and children are currently affected with diabetes mel-
litus, and 60–80% of this population is expected to
develop neuropathy in their life time [7]. Diabetes
induced neuropathy, also known as diabetic periph-
eral neuropathy (DPN), [8] is defined as ‘pain arising
as a direct consequence of abnormalities in the per-
ipheral somatosensory system in people with diabetes’
(IASP) [1,9]. For those with DPN, pain is considered a
risk factor for, as well as a cause of, disability.
A range of pain assessment guidelines have been
developed including the Initiative on Methods,
Measurement and Pain Assessment in Clinical Trials
(IMMPACT) [10] along with assessment guidelines
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from the European Federation of Neurological
Sciences (EFNS) [11], and the NeuPSIG [12]. These
guidelines recommend outcome measures (OMs)
that evaluate a range of issues associated with NeP,
spanning six domains: ‘Pain’, ‘Physical functioning’,
‘Emotional functioning’, ‘Participants’ rating of over-
all improvement’, ‘Participants’ satisfaction with
treatment and symptoms’, and ‘Adverse events’ [13].
In chronic pain conditions, as pain increases it
becomes disruptive to many aspects of a person’s life
[14,15]. Along with assessment of pain relief, assess-
ment of improvement in functional deficits should
always be assessed in these cases, as patients tend to
correlate their recovery with their ability to perform
their normal household physical functions, that is,
their day to day activities.
The choice of which OM to use may be based on
the study group, the purpose of the questionnaire,
its psychometric properties as shown by reliability,
validity, and responsiveness, and on practical con-
siderations (for example, ease of scoring and how
long it takes to complete) [16,17]. The usefulness of
measurement in clinical research and decision-mak-
ing depends on the extent to which clinicians or
researchers can rely on data as accurate and mean-
ingful indicators of behavior or attribute. In order
to be confident about the output of a measure, the
psychometric properties of that particular measure
should be made available [18]. Since a variety of
OMs are available for the above-stated domains, the
quality of the information provided by these meas-
ures depends, in part, on the psychometric proper-
ties of available OMs [19]. Thus knowledge about
the psychometric properties of available OMs in
published trials may provide a useful basis for
selecting the best/most appropriate measurement
instrument for a specific purpose.
The prevalence of NeP is expected to increase in
coming years for a variety of reasons. First with an
estimated increase in the aging population that there
will be concurrent increase in the prevalence of
NeP, which is more prevalent in the elderly. Second
with the advancement of medical science, the sur-
vival rate of patients suffering from cancer, HIV
infection, and diabetes, for example, has increased.
These are known to be leading causes of the devel-
opment of NeP [20,21]. Such factors will lead to
increases in the numbers of people with NeP glo-
bally. These factors underscore the need for devel-
opment of a common set of OMs to inform
questions about treatment effectiveness. For this
study, the tools to be evaluated assessing pain and
physical functions were the modified Brief Pain
Inventory (mBPI-DPN) scale, and the short form
Screening of Activity Limitations and Safety
Awareness (sSALSA) scale; these were chosen based
on their clinical relevance to diabetic participants
(including their pain and physical function).
The mBPI-DPN is a modified form of the original
BPI, a self-administered scale used in clinical pain tri-
als to assess pain severity and its impact on activities
of daily living [14]. The reliability of the modified
BPI scale has been established in various language ver-
sions: a German chronic pain population [22],
Spanish cancer-related pain [23], Taiwanese cancer-
related pain [24], and in an English osteoarthritis
population [25]. However, the reliability of the modi-
fied BPI scale in the English language in the DPN
population has never been reported. The sSALSA
scale covers activity areas such as mobility (feet), self-
care, work (hands), and dexterity (hands). Fifteen of
the 20 questions cover aspects of manual activities,
while the remaining 5 concern activities that often
imply problems for people with affected sensibility in
other body areas. The sSALSA scale was developed for
a population with neuropathy due to leprosy and dia-
betes [26]. However, a careful study of the literature
revealed that the reliability and validity of this scale
have been assessed only in a leprosy population; usage
of the sSALSA scale for DPN has not been given great
attention by researchers in the past and this motivated
the present study. The sSALSA scale is the only scale
which deals with the unique presentation of the DPN:
that is, measuring the effect of loss of sensation on a
person’s ability to carry out activities without injuring
themselves. Though the psychometric properties of
these two OMs have been established in other popula-
tions, this is the first study to investigate their psycho-
metric properties in a DPN population.
2. Study objectives
 Evaluate the relative and absolute reliability of
the mBPI-DPN and sSALSA scale in a group of
patients with chronic DPN.
 Determine the convergent validity for the mBPI-
DPN pain-related interference and sSALSA scale
in adults with DPN.
 Explore the responsiveness for pain and physical
functioning OMs to determine the natural pro-
gression/variation of the DPN disease.
3. Methods
3.1. Design
This study was a prospective, longitudinal cohort
study. Approvals were obtained from the University
of Otago Human Ethics Committee (Health):
reference number H13/041 and Maori Research
Consultation through the Ngai Tahu Research
Committee; all participants signed an informed con-
sent form. The study protocol has been previously
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reported [27]. Participants were recruited from New
Zealand (North and South Island) via advertise-
ments on community boards, and in local newspa-
pers. Invitation letters, along with information
sheets, were sent to the general physicians (GPs) in
the Otago region for referral of potential participants to
this study. Invitation letters and information sheets
were also sent to 15 branches of Diabetes NZ situated
throughout the New Zealand (North Island: Auckland,
Tauranga, Rotorua, Hamilton, Gisborne, New
Plymouth, Napier, Palmerston North, and Wellington;
and in the South Island: Nelson, Christchurch, Timaru,
Oamaru, Dunedin, and Invercargill). A snowball sam-
pling technique (Exponential non-discriminative) as a
chain referral was also followed [28]. All interested vol-
unteers were requested to contact the clinical research
administrator (CRA), at the Centre for Health Activity
and Rehabilitation Research (CHARR), University of
Otago, telephonically or via electronic mail. The CRA
then approached the volunteers (by telephone) and
screened for eligibility. Participants who scored12 on
S-LANSS, suggestive of pain of a predominantly nerve
origin, were eligible to participate in the study [29].
The S-LANSS is a screening tool which has been rec-
ommended by the EFNS to distinguish pain of neuro-
pathic origin, from non-neuropathic sources [11].
3.2. Participants
Inclusion criteria: Adults (18 years and over) with a
confirmed diagnosis of diabetes given by a GP,
associated with chronic ( 3 months) NeP [30] and a
score of 12 on the S-LANNS were included in
the study. Exclusion criteria: Participants who are
unable to comprehend and record OM data
were excluded.
3.3. Questionnaires
3.3.1. Pain outcome measure: the modified brief
pain inventory-diabetic peripheral neuropathy
item and scale score
The mBPI-DPN is a modified form of the BPI, a
self-administered scale used in clinical pain trials to
assess pain severity and its impact on activities of
daily living [14]. It is a numeric rating scale, which
includes a four-item pain severity scale, and a
seven-item pain interference scale. Each BPI item
uses a 0–10 rating anchored at zero for ‘no pain’
and 10 for ‘pain as bad as you can imagine’ for
severity, and a 0–10 scale to measure interference
from 0 ‘does not interfere’ to 10 ‘completely inter-
feres’. Total scores range from 0 to 110, with higher
scores indicating more pain, and pain-related inter-
ference in general activities, mood, walking ability,
normal work, relations with others, sleep, and enjoy-
ment of life.
3.3.2. Physical functional outcome measure: short
form for screening of activity limitation and safety
awareness scale
The sSALSA is a modified form of the original 374
item scale, consisting of 19 different sections,
including self-care, around the house, reading and
writing, getting around, leisure, child care, and
working with tools. The original SALSA and the
sSALSA scale are optimally interview-based instru-
ments, where items in the scale are closed, with
structured questions. The questions reported in the
scale should be asked exactly as they are written.
The literature supports that the sSALSA scale can be
administered by any literate medical or non-medical
worker/volunteer [31]. Since this study was con-
ducted in a developed country (New Zealand) where
all the potential participants were expected to be lit-
erate, and one of the inclusion criteria for this study
was to be able to understand English, the sSALSA
scale was administered as a self-reported OM. Since
the mode of administration of the scale was changed
to a self-report measure, a Question-by-Question
Guide was provided along with the sSALSA scale
(as originally developed to be used by the inter-
viewers to accompany the scale), for the participants
to understand the underlying meaning of the indi-
vidual questions [26]. For the purpose of grading,
participants were asked to report whether a particu-
lar activity was ever carried out by them. If the
response was NO, then they were instructed to
grade the item as zero. However, if the response
was YES, grading was provided by asking further
questions, such as: whether this activity was per-
ceived as easy: Grade 1, a little difficult: Grade 2, or
very difficult: Grade 3. Participants were instructed
that if the activity was physically impossible or
avoided because of a perceived risk of injury, they
should report it as Grade 4, indicating an advanced
degree of activity limitation.
3.3.3. Patient global impression of change scale
PGIC scale is a seven-point Likert scale that asks par-
ticipants to rate their change of symptoms at the fol-
low-up compared to baseline. The participant was
instructed to write down their present chief complaint
and asked to answer the following question, ‘Since
beginning this study, how you would describe the
change (if any) in Activity limitations, Symptoms,
Emotions, and Overall Quality of Life, related to your
painful condition?’ The PGIC has seven possible
answers ranging from zero – ‘No change (or condition
has got worse)’ to seven, indicating – ‘A great deal
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better, and a considerable improvement that has
made all the difference’. Participants were instructed
to circle the number which matched most closely with
their degree of change since participating in this study
for the stated complaint [32].
3.4. Examination procedure
Data were collected at baseline, after a 4-week interval,
and after a 12-week interval. All participants were
asked to complete a baseline questionnaire, providing
some sociodemographic information. Medication
usage for controlling diabetes and nerve pain was
recorded at baseline, and at week four, to monitor
usage during the study. The Charlson Comorbidity
Index was used to assess the presence of other associ-
ated illnesses [33,34]. Each participant was requested
to complete two scales: mBPI-DPN and sSALSA scale
at baseline assessment. On re-assessments, the same
two scales (Pain OM: mBPI-DPN scale and Physical
function OM: sSALSA scale) including the PGIC scale
were sent with instructions to all participants (either
electronically or by mail) for completion. The PGIC
was used as an external criterion for the overall par-
ticipant improvement at 12 weeks follow-up [32].
Participants were instructed to re-send their com-
pleted forms via e-mail/priory stamped enclosed
envelopes to the CHARR within two weeks of receipt.
To increase the response rate, modified Dillman’s
respondent contact strategies were adopted [35].
Under this strategy, if no response was received after
two weeks, two follow-up reminders (telephonic call/
e-mail) were made by the CRA.
4. Statistical analysis
Statistical analysis was performed with the IBM
Statistical Package for Social Sciences (SPSS) version
22 (IBM Corporation, New York, NY, USA) for
Windows. Descriptive statistics were used to sum-
marize demographic characteristics of the DPN
population. The means, 95% CI and standard devi-
ation scores for the mBPI-DPN scale, and the
sSALSA scale evaluated on three testing occasions
(baseline, at 4-week interval, and at 12-week inter-
val) were calculated.
4.1. Analysis for test–retest reliability
Intraclass Correlation Coefficient (ICC2,1), and
Standard Error of Measurement (SEM), and its per-
centage (SEM%), Smallest Real Difference (SRD),
and its percentage (SRD%) were calculated to derive
relative and absolute forms of reliability estimates
for the mBPI-DPN scale, and the sSALSA scale
between two testing occasions (baseline and 4-week
interval) [36]. The criteria used for the estimates of
reliability were: ICC values> 0.75 excellent reliabil-
ity; 0.4> ICC <0.75 good reliability; and ICC values
<0.40 indicated poor reliability [37]. For interpret-
ation of SEM% the following criterion was used:
SEM% ‘20¼ acceptable’ [38]. Additionally, to
assess systematic variation between tests and retest
scores (baseline and 4-week interval), a paired t-test
was performed. Prior to calculating the systematic
bias scores, data were evaluated for assumption of
normality on Kolmogorov–Smirnov (K–S) test, and
Shapiro–Wilk (S–W) test [36]. If test results were
nonsignificant (p> 0.05), it indicated the normal
distribution of data, and if the results were signifi-
cant (p< 0.05), Wilcoxon significant rank test (non-
parametric test) was performed. The statistical level
of significance was set at p< 0.05.
4.2. Analysis for convergent validity for the
mBPI-DPN pain-related interference scale and
sSALSA scale
Pearson’s correlation coefficient [39] and/or
Spearman’s rank correlation [36] analyzed the associ-
ation between these two variables. A coefficient of 1
indicates that the variables (mBPI-DPN pain-related
interference scale and sSALSA scale) are perfectly
positively correlated. The following criteria were used
to assess the strength of associations: 0.00–0.25 little
or no correlation; 0.25–0.50 fair relationship;
0.50–0.75 moderate to good relationship; and above
0.75 good to excellent relationship [39]. The probabil-
ity (p) value was set as p< 0.05 (two-tailed) to exam-
ine the statistical significance of the relationship.
4.3. Analysis for responsiveness: minimal
clinically important difference
Both ‘anchor-based approach’ and the ‘distribution-
based approach’ were adopted to calculate and com-
pare the interpretability scores for the mBPI-DPN
and sSALSA scales. In an anchor-based approach
the ‘within-patient change score’ method was
adopted to obtain the interpretability scores. For the
distribution-based methods, four different measures
to calculate MCID- Standard Error of Measurement
(SEM), Minimal Detectable Change (MDC), Effect
size, and Standardized Response Mean (SRM) were
adopted [40].
The PGIC was considered as an external criterion
at 12-week follow-up [32]. For the purpose of statis-
tical analysis, PGIC scores were clustered into two
main categories: ‘changed’ and ‘unchanged’ based
on previous studies [32]. Participants who scored:
‘5’, ‘6’, or ‘7’ were categorized as ‘changed’. The
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category unchanged’ included participants who
scored ‘1’, ‘2 ’, ‘3 ’, or ‘4’ on the PGIC.
To handle missing data, initially a follow-up
strategy was adopted [39]. Participants who either
failed to report on second assessment or failed to fill
any section of the scales were contacted by tele-
phone, or via e-mail to obtain their readings.
However, if no response was obtained, then the last-
observation-carried-forward method was adopted
[39]. Here the participant’s initial data point (before




In total, 61 volunteers showed interest in participat-
ing in the study (Figure 1).
A total of 38 participants, 24 (63.2%) males and
14 (36.8%) females, with a mean age 62.7 years (SD
15.8) satisfied the inclusion criteria and gave con-
sent to participate in the study. Table 1 presents the
demographic and clinical characteristics of partici-
pants. The mean time since diagnosis with diabetes
was 19.6 years (SD 14.0); mean duration of NeP was
65.8 months (SD 53.8). Less than a third were
employed either part time ( 29 hours per week) or
full-time ( 30 hours per week); N¼ 8 (21.1%) par-
ticipants reported that they were unable to work
due to NeP symptoms. Less than a third of included
participants (N¼ 12/38, 31.6%) were retired. The
mean BMI was 31.34 (range 17.68–47.25) with 21
participants classified as obese (BMI 30) [41]. The
mean total pain severity and interference rating for
the subjects was 47.7 (SD 20.7) (95% CI 40.9–54.5)
at baseline assessment. The mean activity limitation
reported by included participants was 35.6 (SD 11.1)
(95% CI 31.9–39.2) at baseline assessment (Table 2).
Medicinal dosage changes occurred in 10 partici-
pants (n¼ 5 at 4-week, n¼ 5 at 12-week follow-up)
during the study period. During the 4-week follow-
up, three participants had changes in their diabetes
medication dosages (two reductions, and one
increase), two participants had changes in their NeP
medication dosage (one reduction, and one
increase). At 12-week follow-up, four participants
reported an increase in their diabetes-related medi-
cation, and one reported a complete change of their
medicine. None of the participants reported involve-
ment in other forms of treatment during the
study period.
5.2. Test–retest reliability
The total mBPI-DPN scale showed overall good reli-
ability, ICC ¼ 0.61 (95% CI 0.37–0.78); total pain
severity scale, ICC ¼ 0.57 (95% CI 0.31–0.75); and
the total pain-related interference scale, ICC ¼ 0.51
(95% CI 0.24–0.71). Results for SEM and SEM %
varied widely among both of the subscales of mBPI-
DPN measure. SEM (SEM %) values for the total
mBPI-DPN scale ranged from 4.56 (29%) to 12.92
(28%) showing an unacceptably high level of meas-
urement error (Criterion: SEM%  20%). The
SRD% ranged between 81 and 104 percent of the
mean (Table 3). The sSALSA scale showed overall
excellent reliability, ICC ¼ 0.81 (95% CI 0.66–0.89).
SEM (SEM %) values for the short form SALSA
scale were 4.88 (13%) showing an acceptable (that
is, <20%) level of measurement error; SRD % value
for total sSALSA scale was 13.53 (37%).
Table 3 shows the systematic variation of the
mBPI-DPN and sSALSA scales mean scores, along
with a t-test/Wilcoxon signed-rank test comparing
the means at baseline and 4-week follow-up assess-
ments. The mean change score in the mBPI-DPN
pain intensity scale was 1.96 (p value 0.058), for the
mBPI-DPN pain-related interference scale was 1.44
(p value 0.158), and for the total mBPI-DPN scale
was 1.93 (p value 0.061). Since all the p values were
>0.05, assessment scores for the total and subcom-
ponents of the mBPI-DPN scale are not considered
significantly different at baseline and at 4-week fol-
low-up assessments. The mean change scores for
total sSALSA scale was 2.206 (p value 0.027),
showing a significant difference between the baseline
and at 4 weeks.
Subjects who showed their interest 
to participate in the study  
n= (61) 
Subjects provided with the consent 
form and information sheet  
n= (38) 
Assessed for eligibility via telephone 
screening  
n= (54) 
Excluded n= (7) 
n= (2) Not interested; and 
n= (5) Could not contact  
Excluded n= (16) 
n= (14) Scored <12 on S-
LANSS; and 
n= (2) Not interested 
Week 0 Baseline assessment 
n= (38)
Week 4: Follow-up assessment 
n= (38) (100% follow-up) 
Reason for discontinuity n= (3) 
n= (2) Not interested; and
n= (1) Unable to contact
Week 12: Follow-up assessment 
n= (35) (92.11% follow-up) 
Figure 1. Flowchart of the flow of participants during study.
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5.3. Convergent validity
Convergent validity between mBPI-DPN pain-related
interference scale (general activity, walking ability, and
normal work) and sSALSA scale OMs was examined
by comparing these scores using Spearman’s correl-
ation coefficient analysis (Table 4). At baseline assess-
ment, the total mBPI-DPN pain-related interference
scale showed a very low correlation with the sSALSA
scale (r¼ 0.45, p¼ 0.004). Subcomponents of total
mBPI-DPN pain-related interference scale: General
activity (r¼ 0.34, p¼ 0.039), Walking ability (r¼ 0. 36,
p¼ 0.026), and Sleep (r¼ 0.39, p¼ 0.017) were fair to
moderately correlated with sSALSA scale. Only the
normal work subcomponent of the mBPI pain-related
interference scale showed moderate to good correlation
with sSALSA scale (r¼ 0.52, p¼ 0.001). At 12-week
assessment, much stronger correlations were observed
between the subscales of the mBPI-DPN pain-related
interference scale and the sSALSA scale: General activ-
ity (r¼ 0.64, p< 0.001), Walking ability (r¼ 0.54,
p< 0.001), Normal work (r¼ 0.74, p< 0.001), and total
BPI-DPN pain-related interference scale (r¼ 0.62,
p< 0.001) showed moderate to good correlation. Only
the sleep subscale demonstrated a low correlation with
Table 1. Characteristics of participants.
Characteristic (n¼ 38) Range
Age (yr), mean (SD) 62.66 (15.80) 30.30–81.90
Sex, n male (%) 24 (63.20) –
Ethnicity, n (%) – –
New Zealand Europeans 25 (65.80) –
British Europeans 3 (7.90) –
Maori 2 (5.30) –
Indian 5 (13.20) –
Refused to answer 2 (5.30) –
Others 1 (2.60) –
BMI (kg/m2), mean (SD) 31.34 (7.60) 17.68–47.25
Waist to hip circumference ratio 0.93 (0.13) 0.81–1.30
Clinical characteristics – –
Type of diabetes, n Type I (%) 11 (28.90) –
Type of diabetes, n Type II (%) 26 (68.40) –
Type of diabetes, n Type Unknown (%) 1 (2.60) –
Time since diabetes (yr), mean (SD) 19.63 (14.04) 3–53
Time with nerve pain (months), mean (SD) 65.84 (53.80) 5–204
Charlson comorbidity Index, mean (SD) 2.68 (1.80) 1–7
List of treatments availed by participants, n (%) – –
Pharmacological treatment for diabetes 23 (60.50) –
Drugs for nerve pain 16 (42.10) –
Drugs for other health related problems 20 (52.60) –
Diabetic education: blood sugar monitoring, skin care, foot care 7 (18.40) –
Physiotherapy 5 (13.20) –
Diet management 7 (18.40) –
Gym/Sport club participation/Exercise/Activity programme 12 (31.60) –
Others 5 (13.20) –
Table 2. Mean (SD) score on the mBPI-DPN and sSALSA scale by item (n¼ 38).
Item Baseline Score 4th week score 12th week score
mBPI-DPN item scale Mean (SD) Mean (SD) Mean (SD)
Pain severity (0–10) – – –
Worst pain over 24 h 6.26 (2.39) 5.21 (2.44) 5.03 (2.78)
Average pain over 24 h 4.76 (2.11) 3.95 (2.32) 3.66 (2.45)
Least pain over 24 h 2.79 (2.36) 2.45 (2.20) 2.13 (2.03)
Current pain 2.71 (2.37) 2.74 (2.52) 2.97 (2.64)
Total pain severity (0–40) 16.53 (6.94) 14.34 (8.13) 13.79 (8.97)
Pain-related interference (0–10) – – –
General activity 4.24 (3.16) 4.08 (2.38) 4.47 (2.82)
Mood 4.13 (3.25) 3.92 (2.89) 4.26 (2.66)
Walking ability 4.66 (3.31) 4.11 (2.75) 4.29 (2.60)
Normal work 4.00 (3.08) 3.74 (2.37) 3.89 (2.57)
Relations with others 3.16 (3.20) 2.87 (2.67) 3.68 (2.99)
Sleep 5.92 (2.86) 5.00 (3.22) 4.63 (3.23)
Enjoyment of life 5.08 (2.78) 3.97 (2.43) 4.37 (2.50)
Total pain-related interference (0–70) 31.18 (15.82) 27.68 (14.70) 29.61 (15.57)
Total (0–110) 47.71 (20.72) 42.03 (21.26) 43.39 (22.70)
sSALSA scale (1–4) Mean (SD) Mean (SD) Mean (SD)
See 1.42 (0.60) 1.58 (0.64) 1.50 (0.60)
Mobility (feet) 9.00 (4.30) 8.79 (3.86) 2.74 (1.13)
Self-care 4.74 (2.27) 5.11 (2.38) 1.47 (0.73)
Work (hands) 10.63 (4.82) 11.79 (5.61) 1.39 (1.22)
Dexterity (hands) 7.68 (4.05) 7.89 (3.85) 1.79 (0.91)
Total (1–80) 35.58 (11.06) 37.34 (11.52) 38.00 (11.84)
CI: Confidence Interval; hr: hour; mBPI-DPN: modified Brief Pain Inventory for Diabetic Neuropathic Pain; Ssalsa: short form Screening of Activity
Limitations and Safety Awareness scale; SD: Standard Deviation.
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the sSALSA scale (r¼ 0.16, p¼ 0.334). These findings
suggest that the mBPI-DPN pain interference scale and
the sSALSA scale measure the same constructs, and
thus are convergent in nature.
5.4. Responsiveness – minimal clinically
important difference
According to the external criterion used (PGIC scale),
at the 12-week follow-up, n¼ 5/38 (13.16%) partici-
pants reported change in the DPN symptoms, and
n¼ 33/38 (86.84%) reported no change (that is, were
stable). For the two OMs (the mBPI-DPN scale and
sSALSA scale), the mean and standard deviation of
scores at baseline, and at 12 weeks, and the change
scores, are presented as ‘changed’ and ‘unchanged’
participants in Table 5. ‘Unchanged’ corresponds to
no/minimal change on the PGIC scale, and ‘changed’
to major improvement on the scale. Participants who
classified themselves as ‘unchanged’ did not show a
significant difference in their mBPI-DPN pain inten-
sity scores, nor in their pain-related interference
scores (p> 0.05). However, the total mBPI-DPN scale
and the sSALSA scale showed significant differences
between baseline and 12-week assessment (p< 0.05).
Participants categorized as ‘changed’ did not show a
significant difference in the baseline and 12-week
assessments for the mBPI-DPN pain intensity scale,
total scale, and the SALSA scale (p> 0.05), except for
the mBPI-DPN pain-related interference (p< 0.05).
Results of the MCID estimates using four differ-
ent distribution-based approaches – SEM, MDC,
Effect size, and SRM analysis – are given in Table 6.
For the two OMs (the mBPI-DPN scale and the
sSALSA scale), scores of participants who marked
themselves as ‘Unchanged’ on the PGIC scale at 12
weeks were used for this analysis.
6. Discussion
The aim of this study was to investigate the test–retest
reliability, convergent validity, and responsiveness of
the mBPI-DPN and the sSALSA scale for DPN.
6.1. Test–retest reliability
The total and subscales of the mBPI-DPN score met
the predefined criteria of good (>0.40 ICC <0.75)
Table 3. Descriptive and reliability statistics of the mBPI-DPN and sSALSA scales (n¼ 38).
mBPI-DPN scale
sSALSA scale
Pain intensity scale Pain-related interference scale Total mBPI-DPN scale –
Baseline Mean 16.53 31.18 47.71 35.58
(SD) (6.94) (15.82) (20.72) (11.06)
95% CI (14.25–18.81) (25.98–36.38) (40.90–54.52) (31.94–39.21)
4 weeks Mean 14.34 27.68 42.03 37.34
(SD) (8.13) (14.70) (21.26) (11.52)
95% CI (11.67–17.01) (22.85–32.51) (35.04–49.02) (33.56–41.13)
Relative reliability – – – –
ICC2,1 – 0.57 0.51 0.61 0.81
95% CI (LB–UB) (0.31–0.75) (0.24–0.71) (0.37–0.78) (0.66–0.89)
Absolute reliability – – –
SEM – 4.56 11.05 12.92 4.88
%SEM – 29.56 37.55 28.80 13.38
SRD – 12.64 30.63 35.82 13.53
%SRD – 81.93 104.09 79.82 37.09
– – – – – –
Systematic variation – –
t/r value – 1.96 1.44 1.93 2.206a
p value – 0.058 0.158 0.061 0.027
CI: Confidence Interval; ICC: Intraclass Correlation Coefficient; LB: Lower boundary to confidence interval; mBPI-DPN: modified form of Brief Pain
Inventory for Diabetic Peripheral Neuropathic pain; p: level of significance; r value: from Wilcoxon signed rank test; SD: Standard Deviation; SEM:
Standard Error of Measurement; SRD: Standardized Response Mean; t value: from paired sample ‘t’ test; UB: Upper boundary to confidence interval.
aWilcoxon signed rank value, the sum of negative ranks equals the sum of positive ranks.





ability Normal work Sleep
mBPI-DPN pain-related
interference scale
Baseline r value 0.336 0.360 0.517 0.385 0.452
p value 0.039 0.026 0.001 0.017 0.004
12 weeks r value 0.644 0.541 0.741 0.161 0.615
p value 0.000 0.000 0.000 0.334 0.000
mBPI-DPN: modified Brief Pain Inventory for Diabetic Neuropathic Pain; p: level of significance; r: Spearman correlation coefficient; sSALSA: short
form Screening of Activity Limitations and Safety Awareness scale.Correlation is significant at the 0.05 level (2-tailed).Correlation is significant at the 0.01 level (2-tailed).
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reliability. Current findings have both similarities and
differences to previous test–retest evaluations [22–25].
Although there may be variability between studies, pre-
vious results demonstrated that the test–retest reliabil-
ity of the mBPI-DPN scale is highest when
administered over a short time span (that is, hourly or
daily), as compared with the four weeks duration in the
current study, suggesting that these may be the optimal
intervals for assessment with this tool during future.
This was the first study to report on the relative as well
as the absolute forms of reliability for mBPI-DPN scale
in the DPN population. In the current study, the total
short form SALSA scale demonstrated excellent reli-
ability (ICC ¼ 0.81). There are no comparative data
within the literature, as this was the first attempt to
evaluate the test–retest reliability of sSALSA scale in
DPN population.
While both the subcomponents and total mBPI-
DPN scale and sSALSA scale demonstrated good to
excellent relative reliability, the absolute reliability
results (SEM % and SRD %) were not within the
acceptable range (criterion, SRD % 20%). The SEM
value is crucial in the correct interpretation of ICC
results, as it indicates the amount of ‘measurement
noise’. The SEM values for this study suggests that tes-
t–retest differences of <28% for the mBPI-DPN scale
and <13% for the sSALSA scale should be considered
as measurement noise in DPN participants. Similarly
SRD of a test/measure can be useful for clinicians or
researchers in determining whether the change in
score for an individual is real (that is, beyond meas-
urement error) at 95% confidence interval [38]. On
the basis of the SRD% observed in the current study, a
general guideline for DPN patients is that a 79%
change in the pain scores and 37% change in the phys-
ical function scores are indicative of a genuine clinical
change. This higher variability in the absolute reliabil-
ity values represent the subtle differences between two
assessments; thus, the obtained results should be
interpreted with caution.
Collectively it is understood that the test–retest reli-
ability of the mBPI-DPN scale is good; furthermore the
sSALSA scale demonstrated excellent reliability.
6.2. Convergent validity
The aim of the second part of the current study was
to evaluate the validity of the sSALSA scale using
Table 5. Mean scores and its standard deviations (at baseline, and at 12 weeks after baseline), and change scores for mBPI-
DPN item and subscale and sSALSA scales arranged by PGIC categories.
Item (n¼ 33 unchanged;
n¼ 5 changed) PGIC category
Baseline score mean (SD)
95%CI (LB–UB)
Score after 12 weeks
mean (SD) 95%CI (LB–UB)
t/r value
(p value) MCID
Total pain severity (0–40) Un-changed 16.82 (7.11) 14.61 (8.77) 1.68 2.21
(14.30–19.34) (11.50–17.72) 0.103 (0.47–4.90)
Changed 14.60 (5.98) 8.40 (9.34) 1.483a 6.20
(7.17–22.03) (3.20–20.00) 0.138 (3.43–15.83)
Total pain-related
interference (0-70)
Un-changed 30.61 (15.95) 30.88 (15.11) 0.11 0.27
(24.95–36.26) (25.52–36.24) 0.910 (5.17–4.62)
Changed 35.00 (16.08) 21.20 (17.71) 2.032a 13.80
(15.04–54.96) (0.79–43.19) 0.042 (5.74–33.34)
Total mBPI-DPN
item scale (0-110)
Un-changed 47.42 (20.92) 45.48 (21.77) 0.70 1.94
(40.01–54.84) (37.76–53.21) 0.492 (3.74–7.62)
Changed 49.60 (21.52) 29.60 (26.44) 1.753b 20.00
(22.87–76.33) (3.23–62.43) 0.080 (7.29–47.29)
sSALSA scale (1–80) Un-changed 36.52 (11.48) 39.24 (11.99) 2.36 2.73
(32.45 40.58) (34.99 43.49) 0.024 (5.080.37)
Changed 29.40 (4.72) 29.80 (6.98) 0.378a 0.40
(23.54–35.26) (21.14–38.47) 0.705 (3.64–2.84)
CI: Confidence Interval; LB: Lower Boundary to confidence interval; mBPI-DPN: modified Brief Pain Inventory for Diabetic Peripheral Neuropathy;
PGIC: Patient Global Impression of Change scale; p: level of significance; r value: from Wilcoxon signed rank test; sSALSA: The short form Screening
of Activity Limitations and Safety Awareness scale; SD: Standard Deviation; t value: from paired t test; UB: Upper Boundary to confidence interval.
MCID and 95 % CI values set in italics indicate statistically significant differences between mean changes.
aThe sum of negative ranks equals the sum of positive ranks from Wilcoxon signed rank test.
bBased on positive ranks from Wilcoxon signed rank test.
Table 6. MCID values (at 95% confidence intervals) for the subscales of mBPI-DPN scale and sSALSA scale when using four
different distribution-based methods.
Absolute change score using six different MCID
methods of distribution-based approach
Item SEM MDC Effect size SRM
Baseline to 12 weeks follow-up (n¼ 33) – – –
Total pain severity 4.84 13.41 0.31 0.25
Total pain-related interference 9.94 27.54 0.02 0.02
Total mBPI-DPN item scale 11.03 30.58 0.09 0.09
sSALSA scale 4.84 13.42 0.24 0.23
mBPI-DPN: modified Brief Pain Inventory for Diabetic Peripheral Neuropathy scale; MCID: Minimal Clinically Important Difference; MDC: Minimal
Detectable Change; sSALSA: the short form Screening of Activity Limitations and Safety Awareness scale; SEM: Standard Error of Measurement; SRM:
Systematic Response Mean.
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mBPI-DPN pain-related interference scale as the
gold standard. The correlation between sSALSA
scale and the mBPI-DPN pain interference scale was
fair to moderate at baseline assessment. However, a
much stronger correlation (r¼ 0.54–0.74, p< 0.001)
was observed at the 12-week follow-up point. This
increase could be due to the increased variability in
the pain scores, and thus the pain-related interfer-
ence scores at 12 weeks. Based on these results, it is
concluded that sSALSA scale can be used as a sub-
stitute to BPI pain interference scale to measure
physical function in patients with DPN.
Previous studies have highlighted the potential of
the sSALSA scale. When evaluated for its convergent
validity in a leprosy-based NeP population (n¼ 38
participants) against the DASH questionnaire, the
measure showed a very good correlation (Spearman’s
correlation r¼ 0.87, p< 0.001), demonstrating its
ability to be used as a measure of physical activity in
this population [42]. In an another leprosy-based
study (n¼ 25 participants), the sSALSA scale showed
a moderate to good correlation with various measures
of hand functions: Nine Hole Peg test (r¼ 0.77,
p< 0.0005); the Smith Hand Function Evaluation
(r¼ 0.66, p< 0.0005); the Functional Dexterity
Test (r¼ 0.63, p< 0.0005); and the timed scored
Functional Dexterity Test (r¼ 0.54, p< 0.005) [43].
Current findings in the DPN population further valid-
ate the usage of sSALSA scale in the DPN population
as a measure of physical function.
6.3. Responsiveness
The next part of this study identified the range of
MCID values for the pain (mBPI-DPN item scale) and
physical function (sSALSA scale) OMs for the DPN
population. For the anchor-based approach, only
‘within-patients change score’ method was adopted. In
addition, this study compared the four common meth-
ods within the distribution-based approach to help
gain a better understanding of how methodological
variations can alter the interpretability of the MCID;
the different approaches used provided a very different
results (SEM, MDC, Effect Size, and SRM).
SEM: In the current study, SEM was used as one
distribution based method to find the MCID for the
total and subcomponents of the mBPI-DPN and
sSALSA scales. Through this calculation, it is pos-
sible to describe the amount of change that would
need to be observed on the scale to exceed measure-
ment error. The SEM calculated in this study pro-
vides a minimum change score, which indicates a
real change in a patient, rather than the measure-
ment error alone [44].
MDC: As only unchanged participants were
assessed to calculate the MCID, it was assumed that
for calculating the minimal important difference in
the mBPI-DPN scale, and in the sSALSA scale, the
MCID value should exceed the MDC values. Thus
participants with a change scoreMDC have a
chance that no real change has happened in their
clinical condition. The MDC is considered as a con-
servative method for calculating MCID, as the meas-
urement error is multiplied by 2 at 95% confidence
intervals, accounting for the so-called ‘background
noise’. In the current study, MDC ¼ 13.4 points
was calculated for mBPI-DPN pain intensity scale
(0–40 points scale), which means a change of more
than 13.4 points could be considered as a MCID for
this subscale. Similarly for the mBPI-DPN pain
interference scale (0–70 points scale), MDC ¼ 27.5;
for the total BPI-DPN scale (0–110 points scale),
MDC¼ 30.6, and for total sSALSA scale (1–80
points scale), MDC ¼ 13.4 was calculated.
Effect size: For the mBPI-DPN pain intensity scale,
the mBPI-DPN pain-related interference scale, total
mBPI-DPN scale, and sSALSA scale at all the respect-
ive assessments, an effect size of 0.20< 0.50 was
observed, showing that there was a very small effect
change in pain and physical function scores over
time, as expected. Because of the smaller effect size
values, it could be stated that for the 12-week study
duration, no significant change of pain or physical
function status occurred in the studied population.
SRM: In the current study, the mBPI-DPN pain
intensity scale, the mBPI-DPN pain-related interfer-
ence scale, the total mBPI-DPN scale, and the
sSALSA scale were believed a priori to be likely not
to change, as no intervention was involved. Using
SRM for all these outcomes, a very small change
<0.20 was observed, showing that there was a very
small effect change in the pain and physical function
scores over time.
The above methods produced a variability in the
MCID scores for the two used OMs (mBPI-DPN
scale and sSALSA scale). The possible explanation
for this variation in the MCID, according to the
methods of estimation, can be due to the multiple
reported conceptual and methodological differences
[45]. Furthermore, baseline scores of the measures,
as well as the demographics of the studied popula-
tion, may have an effect in MCID values as the
more extreme baseline scores will have lower SEM
and therefore smaller MDCs. [40,46]. In reviewing
MCID estimates for other pain scales and in other
pain populations, findings appear to be consistent
with findings related to mBPI-DPN presented in
this study. For comparing findings of this respon-
siveness study, no comparative data were available
as this is the first study to calculate MCID of the
pain (mBPI-DPN scale) and physical function
(sSALSA scale) OM in DPN. The only comparative
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data available are from fibromyalgia and cancer-
related populations.
In this study, a range of MCID for pain and
physical function OMs have been presented. In
research a MCID value has to be chosen a priori to
judge which changes are worthwhile to detect. In
practice, an MCID value can be used to interpret
results of a treatment [47]. Capturing responsiveness
to change is a very important property of an OM. A
particular measure could be oversensitive and pick
up small or unimportant changes in health.
Alternatively, a particular questionnaire could be
under sensitive and miss important changes because
they are small [44]. Thus ongoing research to
understand how best to measure change for these
methodological studies is required. The analysis
used in this study has supported the view that the
choice of statistic will affect the description of
responsiveness for any OM. For the same data in
the same patients, we have demonstrated a variation
in the responsiveness values using different statistics.
These findings are in concordance with the available
literature [44]. These results do not confirm which
approach is better, as arguments can be made in
either direction. Though there is a significant differ-
ence in the findings of these two methods,
approaches directed toward combining the distribu-
tion- and anchor- based methods should be the
focus of clinical reports [48,49].
6.4. Limitations of the present study
While results for this reliability study are good, there
are several limitations which need to be acknowledged.
The target sample of 63 participants for the reliability
study was not met (as calculated by Walter’s equation)
[27,50], which potentially threatens the statistical sig-
nificance of the present results. For the present study,
the included participants demonstrated a good degree
of heterogeneity in terms of age, severity of symptoms,
and duration of symptoms, and the included sample
size is similar to previous studies in the field [24,51].
However, it is acknowledged that while performing the
data analysis, how alteration of medication may have
impacted on responsiveness or reliability was
not considered.
For the responsiveness study, from n¼ 38
recruited participants, just 5 participants identified
themselves ‘as being changed from baseline asses-
sment’ which may have affected the precision esti-
mates. As intensity of pain is an important factor,
the MCID was planned to be estimated for mild,
moderate, and severe levels separately. However, as
only a very small number of participants were
recruited for this study, it was not possible to per-
form the sub analysis on such small numbers.
Similarly for the various available anchor-based
approaches, only ‘within-patient change score’ was
used in this study. For the other available methods,
‘between patient change score, ‘ROC curve’, and the
‘social comparison approach’, statistical analysis was
not possible because of the smaller sample size.
6.5. Future research recommendations
In this study, a number of the psychometric proper-
ties of pain and physical function OMs were
assessed in a DPN population. Of the six core out-
come domains recommended by the IMMPACT
[10], the EFNS [11] and NeuPSIG [12] guidelines,
psychometric properties for only first two domains,
that is, pain and physical functioning, were
addressed and investigated. Further research study-
ing various OMs in the other four domains, i.e.
‘Emotional functioning’, ‘Participants’ rating of
overall improvement’, ‘Participants’ satisfaction with
treatment and symptoms’, and ‘adverse events’, and
the psychometric properties of those OMs,
is indicated.
Validation is an ongoing process. In order to
generalize results of the present study, a similar pro-
cedure should be repeated on a larger (100) num-
ber of participants. Such a study is required to
enable more detailed statistical analysis of OMs to
investigate their psychometric properties. Such a
large number of participants would necessitate an
extended recruitment period. Future investigators
exploring the psychometric properties of various
OMs should consider various time points (from
days to weeks, to months to years) to capture the
natural progression of the underlying disease. The
inclusion of scales quantifying mood, sleep pattern,
and health-related quality of life may provide a bet-
ter understanding of influence of pain on
these domains.
Since there has been much debate over whether
to use the anchor- or distribution-based approach in
determining the MCID of an OM, future research
attempting to establish MCID values for any self-
reported measure should use objective (clinician
reported) anchors, or a combination of subjective
(patient reported) and objective anchors, rather than
linking two self-reported instruments to each other
in the belief that one of the two (such as global rat-
ing of change, GRC, or patient global impression of
change, PGIC) can be used as an ‘objective’ anchor
of outcome. In the literature, most of the studies
have been performed to evaluate MCID for signifi-
cant change or improvement. Future research
should evaluate if the MCID value for improvement
is the same as for deterioration.
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6.6. Clinical implications
Results from this study add to the body of evidence
surrounding the usability of various OMs used to
evaluate the effectiveness of various treatments of
NeP and DPN, which the clinician/researcher can
use as part of the informed decision-making process
that underpins evidence-based practice. This obser-
vational study was designed and undertaken to
investigate the psychometric properties of OMs for
the assessment of DPN. With the usage of these reli-
able and valid multidimensional PROMs, patients/
research participants may themselves track the pro-
gression (improvement/deterioration) of their condi-
tion/clinical symptoms.
7. Conclusions
This study was developed to explore and investi-
gate the psychometric properties of various pain
and physical function OMs in DPN population.
Despite the limitations and problems encountered
during completion of the study, results have pro-
vided evidence to add to the scientific basis sur-
rounding the use of pain and physical functioning
OMs in the DPN population. To assess pain and
pain-related physical functional limitation is very
important in any condition associated with sensory
loss. This study has provided preliminary values
for test–retest reliability, convergent validity, and
responsiveness (capturing the natural progression/
variation of the disease) of mBPI-DPN and
sSALSA scales in the DPN population. However,
issues around assessing the responsiveness under
the influence of clinical treatment remain. Since
the different modes of administration of question-
naires can have an important influence on the
quality of the information collected, it is acknowl-
edged that the findings of the sSALSA scale in this
study may not be generalizable to a wider popula-
tion, before further validation. However, standard-
ization of these measures in a larger population
may provide the gold standard to use in research
and clinical practice.
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